Sales

(CHF million)

EBITDA

(CHF million)

EBITDA MARGIN

(in % of sales)

INTRODUCTION

The last two years have been exceptional, for the world as well as for Tecan. We were called upon to help tackle the first pandemic where lab automation would play a crucial role. And our contribution was decisive in the global response to COVID-19. But this is only the beginning. We have known for decades that several health challenges need attention beyond infectious diseases, notably cancer, rare and hereditary diseases, metabolic and cardiovascular diseases, among many others. The healthcare challenge will intensify as populations requiring healthcare grow larger and older. Innovations that facilitate early detection, disease prevention and precision therapies provide the prospect of alleviating the burden of both patients as well as the cost of healthcare. The necessary innovations and targeted medicines will come of age in research labs and then make their way into standard medical practice.

MARKETS & STRATEGY

Tecan is a pioneer and has been the market leader in laboratory automation for more than 40 years. It enables customers in the life science research and diagnostics sectors to put seminal discoveries into practice in their daily business thanks to laboratory instruments and comprehensive automation solutions - from basic science to prevention, diagnosis and treatment of diseases.

LIFE SCIENCE BUSINESS

Tecan is the market leader and a pioneer in laboratory automation. Tecan has offered a wide range of laboratory instruments and automated workflow solutions for use by pharmaceutical and biotechnology companies, government research institutions and universities, diagnostic laboratories, and scientists from numerous applied markets for more than 40 years. In 2021, the Life Sciences Business segment represented 51% of total sales of the Tecan Group.

PARTNERING BUSINESS

Tecan not only provides end customers with automation solutions, but is also a leading developer and manufacturer of OEM instruments and components which partner companies sell under their own name. Tecan has been operating its OEM business since the Company was founded over 40 years ago. With the acquisition of Paramit Corporation, a leading OEM developer and manufacturer of medical devices and life sciences instruments, Tecan’s Partnering Business expanded significantly its commercial reach, its capabilities and its US and Asia presence. Including Paramit, this business segment's share of total Tecan Group sales increased to 49% in 2021.

SUSTAINABILITY

By pursuing sustainable corporate practices, Tecan is looking to secure the longterm expansion and prosperity of the Company for the benefit of all interested parties. Tecan sees sustainable corporate practices as more than just a series of individual measures. Instead, it shapes all corporate processes and unites economic, regulatory, ecological and social aspects. Today, this holistic approach is often structured in the three dimensions – Environmental, Social and Governance, or short ESG. Sustainability in this context is a mindset that must be deeply embedded in the business, its structures and procedures – in other words, in the corporate culture. This is the case at Tecan.

CORPORATE GOVERNANCE

Information pursuant to the SIX Swiss Exchange Directive on Information Relating to Corporate Governance.

COMPENSATION REPORT

This Compensation Report describes Tecan's compensation principles and system. It provides information about the method of determining compensation and discloses the compensation awarded during 2021 to the members of the Board of Directors and the Management Board. It complies with the Ordinance against Excessive Compensation in Listed Stock Companies (OeEC), the standard relating to information on Corporate Governance of the SIX Swiss Exchange, and the principles of the Swiss Code of Best Practice for Corporate Governance of the Swiss national federation economiesuisse.

FINANCIAL REPORT

In the year under review, the full-year order entry increased by 12.9% to CHF 965.4 million (2020: CHF 855.2 million), or by 13.0% in local currencies. Following a surge in orders for product lines supporting the global fight against the coronavirus pandemic in 2020, orders were only down 1.5% in Swiss francs and 1.4% in local currencies year-on-year on an organic basis, i.e. excluding Paramit's order entry in the last five months of the year. The effect of the high COVID-related orders in the prior-year period was particularly visible in the second half of 2021. Here, organic order entry was 18.4% below the prior-year figure in Swiss francs and 18.6% in local currencies. Including Paramit, however, order entry grew by 7.2% in Swiss francs and by 6.9% in local currencies in the second half of the year.

Annual Report 2021

EN DE